(Updates with share price movement in headline and first paragraph.) ADMA Biologics (ADMA) shares rose by more than 10% in Thursday afternoon trading, a...
ADMA Biologics (ADMA) reported a Q2 diluted loss late Wednesday of $0.07, narrowing from a $0.15 loss a year earlier. Analysts polled by Capital IQ...
...
...
| Address | 465 State Route 17 South Ramsey, New Jersey 07446 |
| Phone | +1.201.478.5552 |
| Number of Employees | 318 |
| Recent SEC Filing | 08/10/2022 8-K |
| President, Chief Executive Officer & Director | Adam S. Grossman |
| Operations Director | Atkinson Vernon |
| Chief Financial Officer & Executive Vice President | Brian Lenz |
| Vice President-Compliance & Clinical Operations | Kaitlin Kestenberg |
| Price Open | $2.35 |
| Previous Close | $2.40 |
| 52 Week Range | $1.01 - 2.48 |
| Market Capitalization | $473.2 M |
| Shares Outstanding | 196.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.40 |
| Beta vs. S&P 500 | N/A |
| Revenue | $17.0 M |
| Net Profit Margin | -66.44% |
| Return on Equity | -60.28% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
